These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 15228675)
41. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. de Fabritiis P; Amadori S; Calabretta B; Mandelli F Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986 [TBL] [Abstract][Full Text] [Related]
42. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. Baba M; Iishi H; Tatsuta M Int J Cancer; 2000 Jan; 85(2):260-6. PubMed ID: 10629087 [TBL] [Abstract][Full Text] [Related]
47. Challenges and Advances in Gene Therapy Approaches for Neurodegenerative Disorders. Donde A; Wong PC; Chen LL Curr Gene Ther; 2017; 17(3):187-193. PubMed ID: 29034834 [TBL] [Abstract][Full Text] [Related]
48. Pharmacology of antisense oligonucleotide inhibitors of protein expression. Cooper SR; Taylor JK; Miraglia LJ; Dean NM Pharmacol Ther; 1999; 82(2-3):427-35. PubMed ID: 10454217 [TBL] [Abstract][Full Text] [Related]
50. Towards the structure-based design of oligonucleotide therapeutics. Egli M Adv Enzyme Regul; 1998; 38():181-203. PubMed ID: 9762353 [No Abstract] [Full Text] [Related]
51. Strategy for designing specific antisense oligonucleotide sequences. Mitsuhashi M J Gastroenterol; 1997 Apr; 32(2):282-7. PubMed ID: 9085184 [TBL] [Abstract][Full Text] [Related]
52. The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. Stone LS; Vulchanova L Adv Drug Deliv Rev; 2003 Aug; 55(8):1081-112. PubMed ID: 12935946 [TBL] [Abstract][Full Text] [Related]
53. [Molecular therapy for vascular disease using an oligonucleotide-based strategy]. Miyake T; Morishita R Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):158-62. PubMed ID: 17379964 [No Abstract] [Full Text] [Related]
54. Rationally designing antisense therapy to keep up with evolving bacterial resistance. Kotil S; Jakobsson E PLoS One; 2019; 14(1):e0209894. PubMed ID: 30645595 [TBL] [Abstract][Full Text] [Related]
56. The chemical evolution of oligonucleotide therapies of clinical utility. Khvorova A; Watts JK Nat Biotechnol; 2017 Mar; 35(3):238-248. PubMed ID: 28244990 [TBL] [Abstract][Full Text] [Related]
57. Potential treatments for genetic hearing loss in humans: current conundrums. Minoda R; Miwa T; Ise M; Takeda H Gene Ther; 2015 Aug; 22(8):603-9. PubMed ID: 25781649 [TBL] [Abstract][Full Text] [Related]
59. European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease. O'Brien SG; Kirkland MA; Goldman JM Eur J Cancer; 1994; 30A(8):1160-4. PubMed ID: 7654449 [No Abstract] [Full Text] [Related]
60. Antisense oligonucleotide therapies: are they the "magic bullets"? Ma DD; Doan TL Ann Intern Med; 1994 Jan; 120(2):161-3. PubMed ID: 8256976 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]